Preliminary Analysis of Comorbidity Risk Scores and Immune Aging Markers in Women over 45 Years old Living with or without HIV in the CARMA Cohort in British Columbia

Tetiana Povshedna, Maya Rosenkrantz, Anthony Y.Y. Hsieh, Jonathan Steif, Arianne Albert, Evelyn J. Maan, Beheroze Sattha, Ariel Nesbitt, Shanlea Gordon, Jerilynn Prior, Deborah M. Money, Melanie C.M. Murray, Neora Pick; Hélène C.F. Côté, for the CIHR Team Grant on Cellular Aging and HIV Comorbidities in Women and Children and the CARMA (Children and Women: AntiRetrovirals and Markers of Aging) cohort









Introduction

<u>RATIONALE</u>: People living with HIV are at higher risk of age-related comorbidities, even when treated with cART. There are limited data describing **multiple comorbidity scores** for risk prediction in women living with HIV (**WLWH**).







OBJECTIVE: to compare, between **WLWH** and **HIV-negative control women**, the risk scores and immune aging markers - **leukocyte telomere length** (LTL) and **mitochondrial DNA** (mtDNA) content.

▼ Figure 1. Age distribution of study participants (median, IQR).
WLWH were younger than HIV-negative controls. The age of 59 excluded controls did not significantly differ from the 81 HIV-negative controls included in the study.


Study measures and demographics


Risk Score	Definition	Number of participants with score, n (%)*	
		WLWH n=122	HIV-negative controls n=81
Framingham Risk Score (FRS)	10-year risk of cardiovascular event (n=197)	108 (93)	64 (79)
Aspartate aminotransferase-to-platelet ratio (APRI)	Marker of liver fibrosis	119 (98)	73 (90)
Canadian Association of Radiologists and Osteoporosis Canada (CAROC)	10-year risk of a fragility fracture for women >50y (n=145)	72 (89)	52 (81)
Liver-related death risk (LRD) score	Liver-related death risk in HIV/HCV co-infected individuals (n=53)	49 (92)	
Chronic Kidney Disease (CKD) prediction score	Risk of chronic kidney disease (n=115)	115 (100)	
Veterans Aging Cohort Study (VACS) index	5-year risk of all-cause mortality	119 (98)	

Risk scores were calculated for **different subsets** of participants based on the clinical data available.

LTL and mtDNA were measured for **WLWH** n=120 (98%) and **HIV-negative controls** n=78 (96%)

Demographic characteristics of study participants (%)





^{*} Updated with more risk score data compared to the abstract




Table 2. Risk scores specific for WLWH

Liver-related death risk score, median [IQR] 5.5 [4.5-6.5] low (<5.5), n (%) 20 (40.8) medium-low (5.5-8.5), n (%) 20 (40.8) medium-high (8.5-10.5), n (%) 6(12.2)high (>10.5), n (%) 3(6.2)Chronic kidney disease risk, median [IQR] 7.0[3.0 - 12.0]low (<0), n (%) 7 (6) medium (0-4), n (%) 27 (23) 81 (71) high (≥5), n (%) VACS 5-year mortality risk (%), median [IQR] 10.8[6.6 - 21.2]

- A larger proportion of WLWH had APRI>0.7 compared to controls, indicating higher risk for hepatic fibrosis
- A larger proportion of WLWH had moderate/high CAROC scores compared to controls, indicating higher risk for 10-year fracture
- FRS, which estimates 10-year risk of cardiovascular disease, **did not differ** between groups
- WLWH had shorter LTL than controls, but no difference in mtDNA content was detected
- Among WLWH, 18.4% were at medium-to-high risk of liver-related death
- Among WLWH, 71% were at high risk of chronic kidney disease
- Among **WLWH**, the VACS index predicted a 10.8 [6.6-21.2]% risk of 5-year all-cause mortality

Conclusions

In our study, despite the fact that **WLWH** were younger than **HIV-negative controls**, we observed:

Among WLWH vs. HIV-negative controls:



shorter LTL



higher risk scores for liver disease



higher risk scores for bone disease

In addition, for **WLWH** only:



18.4% at medium-to-high risk of liver-related death



71% at high risk of chronic kidney disease



10.8% median risk of 5-year all-cause mortality

No differences in cardiovascular risk and mtDNA content were detected.

Further research is needed to determine how to better predict and prevent aging comorbidities in this population.

Acknowledgments: Côté Lab members; CARMA study participants, investigators and staff